On-Demand Webinar: NAb vs TAb Assays in Gene Therapy Development: Key Considerations For Assessing Immunogenicity

With pre-existing immunity to viral vectors presenting a major challenge to the delivery of life-changing gene therapies, developing an assay to assess humoral immunogenicity. But, how can you determine whether a NAb or Tab assay is best? Deb Phippard, PhD, Chief Science Officer, and Travis Harrison, PhD, Vice President, Bioassay Solutions, Precision for Medicine, offer guidance in this must-see webinar.